Summary
Antiphospholipid antibodies (aPL) are found in a suggest that aPL can contribute to atheroma development by targeting some of the sequential steps variety of autoimmune diseases, and are thought to predispose to arterial and venous thrombosis. These that constitute early atherogenesis. If substantiated by large-scale clinical trials, the pro-atherogenic antibodies, when investigated in different assays in vitro, activate endothelial cells and promote uptake properties of aPL may merit screening and intervention programs in selected populations. of modified LDL to macrophages. These observations
In 1993, the Lancet carried an article by Vaarala (predominantly those requiring the co-factor b2GPI for binding) being more strongly associated with and colleagues which suggested that some antiphospholipid antibodies were capable of cross-reacting thrombosis. A more recent clinical observation was that aPL cross-reacted with oxLDL were more closely with oxidized low-density lipoprotein (oxLDL).1 This finding focused attention on the reports of accelerassociated with arterial than with venous thrombosis.4 If proved correct, this observation has implicaated arterial disease seen in individuals with the antiphospholipid (Hughes) syndrome, and has protions, not only for therapy in lupus and in Hughes syndrome, where arterial disease (especially stroke), vided a new line of atheroma research.2 Since the description of the syndrome in 1983,3 it has been is currently treated with warfarin to a high INR,5 but also more broadly in terms of the pathogenesis and clear that its many features include venous and arterial thrombosis. This propensity, both to arterial prophylaxis of atheroma. The formation of atheroma is increasingly recogthrombosis and accelerated arterial disease, had of course, long been recognized in lupus, and a variety nized as an inflammatory process in the arterial wall, including the accumulation of macrophages of hypotheses had been put forward-notably as an effect of long-term steroid therapy. It now seems and activated T-lymphocytes.6 A high oxidative capacity in the arterial wall leads to oxidationlikely that the strongest arterial risk factor, both in SLE and in Hughes syndrome (antiphospholipid mediated endothelial injury and to a vital decrease in the physiological function of the endothelium.7 It syndrome) is the presence of antiphospholipid antibodies (aPL). Further, it is clear that there are is an attractive working hypothesis, therefore, to assume that antibody responses to oxidized plasma 'subjects' of aPL with different specificities-some proteins, such as oxLDL, b2GPI, prothrombin or the atherosclerotic process, the creation of a prothrombotic 'atmosphere' by aCL can contribute heat-shock proteins may influence this inflammatory reaction and the associated thrombotic risk in atheroto atherogenesis. We have recently tested the hypothesis that aCL sclerosis.
The association of 'autoimmune' aPL with throminduced by immunization with human b2GPI affect atherosclerosis.17 Indeed, transgenic mice lacking botic events has been documented so consistently that their causal role in establishing a prothrombotic the LDL receptor were found to develop accelerated atherosclerosis upon immunization with b2GPI. This state is highly suggested. Indeed, well-conducted clinical trials have shown that the occurrence of aPL animal model substantiated the link between the anti-b2GPI response and atherosclerosis.18 However, can be considered as an independent risk factor for myocardial infarctions8 and cerebral strokes.9 These if aPL can be found to possess proatherogenic properties, population screening programs may charfindings have prompted an elaborate effort by many investigators to determine the mechanism by which acterize risk groups which may, in the future, benefit from regimens aimed at reducing antibody titers or aPL induce thrombosis. Activation of endothelium cells10 and platelets,11 and induction of tissue factor12
to intervening with its atherogenic effects. have all been suggested as possible mechanisms for the prothrombotic diathesis. An interesting point which relates to these findings is the requirement of to cross-react with oxLDL1 and some have even In a recent study, b2GPI-reactive aPL were shown 
